SciSparc Ltd. Announces Intent to Acquire Major Israeli Vehicle Importer

TEL AVIV, Israel, Dec. 07, 2023 -- SciSparc Ltd. SPRC, a specialized clinical-stage pharmaceutical company, today revealed its plans to acquire a prominent vehicle importer in Israel, indicating a significant broadening of its strategic operations. Focusing on the development of central nervous system disorders and rare diseases treatments, SciSparc is at the forefront in the use of cannabinoid molecules for drug development.

Expanding Through Strategic Acquisition

SciSparc Ltd. is taking a bold step to diversify its business activities by expressing interest through a non-binding letter of intent to purchase one of Israel's leading vehicle importers. This move showcases SciSparc's commitment to exploring new markets and leveraging its business acumen beyond the pharmaceutical sector. The acquisition is expected to provide substantial growth opportunities and increase shareholder value over time.

About SciSparc Ltd. SPRC

Based in Tel Aviv, SPRC operates as a specialized clinical-stage pharmaceutical entity. Its primary focus lies in crafting innovative therapies aimed at various central nervous system disorders and rare diseases. The company's drug development efforts are centered around cannabinoid molecules, reflecting a niche area of expertise within the pharmaceutical industry.

SciSparc, acquisition, pharmaceutical